UPDATE: Hearing CyberArk Rejected an $88 Offer from Checkpoint Software
Charles Gross , Benzinga Staff Writer
Sentiment: Strong Buy
Ironwood Pharmaceuticals Whittled Down
Tolerability data for Synergy Pharma’s chronic idiopathic constipation treatment seem to top Ironwood’s Linzess.
Synergy Pharmaceuticals ( SGYP ) reported positive data for plecanatide in a Phase 3 study of 1,346 patients with chronic idiopathic constipation (CIC). Synergy Pharma’s results are favorably to the resultsfrom Ironwood’s two CIC trials.
Also importantly, tolerability data to favor plecanatide over Linzess.
Go to nasdaq after hours
In company news, Delcath Systems ( DCTH ) the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting.
The Fly On The Wall
Breaking News Feed
6:54 AMDeutsche Bank views worldwide license and collaboration arrangement with Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) as a positive and reiterates $25.00 Target on ACHN.
Apr 24, 2015 AISLING CAPITAL II LPBeneficial Owner (10% or more) 67,469 Indirect Sale at $106.10 - $108 per share. 7,223,0002
Apr 24, 2015 GOLDSTEIN DOV A MDDirector 67,469 Indirect Sale at $106.10 - $108 per share. 7,223,0002
Apr 23, 2015 AISLING CAPITAL II LPBeneficial Owner (10% or more) 150,000 Indirect Sale at $109.10 per share. 16,365,000
Apr 23, 2015 GOLDSTEIN DOV A MDDirector 150,000 Indirect Sale at $109.10 per share. 16,365,000
Mar 20, 2015 DOMAIN PARTERS VII L PBeneficial Owner (10% or more) 350,000 Direct Disposition (Non Open Market) N/Mar 19, 2015 ENRIGHT PATRICK GDirector 500,000 Indirect Sale at $110.01 - $116.05 per share. 56,515,0002